Table 3.
Placebo (N = 44) | Erenumab 140 mg IV (N = 44) | |
---|---|---|
Adverse events, n (%) | ||
Any | 14 (32) | 12 (27) |
Serious | 1 (2) | 0 (0) |
Fatal | 0 (0) | 0 (0) |
Safety analyses set; all patients randomized who received at least 1 dose of study drug.
Placebo (N = 44) | Erenumab 140 mg IV (N = 44) | |
---|---|---|
Adverse events, n (%) | ||
Any | 14 (32) | 12 (27) |
Serious | 1 (2) | 0 (0) |
Fatal | 0 (0) | 0 (0) |
Safety analyses set; all patients randomized who received at least 1 dose of study drug.